资源类型

期刊论文 184

会议视频 6

年份

2023 16

2022 18

2021 26

2020 18

2019 17

2018 6

2017 10

2016 6

2015 9

2014 15

2013 2

2012 8

2011 6

2010 6

2009 8

2008 3

2007 9

2000 1

1999 1

展开 ︾

关键词

临床试验 6

有效性 4

肠道菌群 4

COVID-19 3

临床特征 3

人工智能 3

医学 3

安全性 3

中药 2

临床医学 2

免疫疗法 2

前沿技术与中医药创新发展 2

医学教育 2

新冠病毒肺炎 2

新型冠状病毒肺炎（COVID-19） 2

治疗 2

2019-nCoV 1

3-DR-IUD 1

BNCT 1

展开 ︾

检索范围：

排序： 展示方式：

Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patientswith pneumoconiosis: a pilot double-blind, randomized, and placebo-controlled study

《医学前沿（英文）》 2022年 第16卷 第5期   页码 736-744 doi: 10.1007/s11684-021-0870-5

摘要： Effective therapy options for pneumoconiosis are lacking. Traditional Chinese medicine (TCM) presents a favorable prospect in the treatment of pneumoconiosis. A pilot study on TCM syndrome differentiation can evaluate the clinical efficacy and safety of TCM and lay a foundation for further clinical research. A double-blind, randomized, and placebo-controlled trial was conducted for 24 weeks, in which 96 patients with pneumoconiosis were randomly divided into the control and treatment groups. Symptomatic treatment was conducted for the two groups. The treatment group was treated with TCM syndrome differentiation, and the control group was treated with placebo. The primary outcomes were the six-minute walking distance (6MWD) and the St. George Respiratory Questionnaire (SGRQ) score. The secondary outcomes were the modified British Medical Research Council Dyspnea Scale (mMRC), Chronic Obstructive Pulmonary Disease Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), and pulmonary function. Only 83 patients from the 96 patients with pneumoconiosis finished the study. For the primary outcome, compared with the control groups, the treatment group showed a significantly increased 6MWD (407.90 m vs. 499.51 m; 95% confidence interval (CI) 47.25 to 135.97; P <0.001) and improved SGRQ total score (44.48 vs. 25.67; 95% CI −27.87 to −9.74; P <0.001). The treatment group also significantly improved compared with the control group on mMRC score (1.4 vs. 0.74; 95% CI −1.08 to −0.23; P =0.003), CAT score (18.40 vs. 14.65; 95% CI −7.07 to −0.43; P =0.027), and the total symptom score (7.90 vs. 5.14; 95% CI −4.40 to −1.12; P <0.001). No serious adverse events occurred. This study showed that TCM syndrome differentiation and treatment had a favorable impact on the exercise endurance and quality of life of patients with pneumoconiosis.

关键词： pneumoconiosis     randomized controlled trials     traditional Chinese medicine    

HTML PDF 收藏

A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against

PAN Jiangang, ZHOU Xing, CHEN Zhiguang, HAN Ruifa

《医学前沿（英文）》 2008年 第2卷 第3期   页码 259-263 doi: 10.1007/s11684-008-0049-3

摘要： Meta-analysis was used to determine whether maintenance intravesical bacillus Calmette-Guerin (BCG) could reduce recurrence after transurethral resection of tumor 1 grade 3 (T1G3) superficial bladder cancer. All available published data of randomized clinical trials comparing transurethral resection plus intravesical BCG to either resection alone or resection plus another treatment on the treatment results in patients with superficial bladder cancer of T1G3 were selected for analysis. Both the fixed effects model and random effects model were applied, and the odds ratio () with its 95% confidence interval (CI) was used as the effect size estimate. Sensitivity analysis and publication bias determination were performed by funnel plots and comparing s of different models. Within the follow-up period, 375 of 915 (41.0%) BCG-treated patients and 332 of 733 (45.3%) non-BCG-treated patients developed tumor recurrence. In the combined results, a statistically significant difference in the s for tumor recurrence between the two treatment groups was found (randomized model combined effect 0.58, 95% CI 0.41 to 0.83, = 0.003). The stratified meta-analysis did not show any statistically significant confounding effects on the results when stratified by BCG strains. The randomized model combined effect of Pasteur F and other strains were 0.50 (95% CI 0.26 to 0.95, = 0.04) and 0.63 (95% CI 0.40 to 0.99, = 0.04), respectively. Therefore, we came to the conclusion that adjuvant maintenance instillation BCG combined with transurethral resection of bladder tumor (TURBT) is an effective conservative treatment for preventing recurrence of T1G3 bladder cancer.
HTML PDF 收藏

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR

Wenjie Zhu, Binghe Xu

《医学前沿（英文）》 2021年 第15卷 第2期   页码 208-220 doi: 10.1007/s11684-020-0795-4

摘要： New targeted therapies have been developed to overcome resistance to endocrine therapy (ET) and improve the outcome of HR /HER2 advanced breast cancer (ABC). We conducted a meta-analysis and systemic review on randomized controlled trials evaluating various targeted therapies in combination with ET in HR /HER2 ABC. PUBMED and EMBASE databases were searched for eligible trials. Hazard ratios (HRs) for progression-free survival (PFS), odds ratios (ORs) for objective response rate (ORR), clinical benefit rate (CBR), and toxicity were meta-analyzed. Twenty-six studies with data on 10 347 patients were included and pooled. The addition of cyclin-dependent kinase 4/6 inhibitors to ET significantly improved median PFS (pooled HR= 0.547, <0.001), overall survival (pooled HR= 0.755, <0.001), and tumor response rates (ORR, pooled OR= 1.478, <0.001; CBR, pooled OR= 1.201, <0.001) with manageable toxicities (pooled OR= 3.280, <0.001). The mammalian targets of rapamycin inhibitors and exemestane were not clinically beneficial for this pooled population including ET-naïve and ET-resistant patients. Moderate improvement in PFS (pooled HR= 0.686, <0.001) yet pronounced toxicities (pooled OR= 2.154, <0.001) were noted in the combination of phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors with fulvestrant. Future studies are warranted to optimize the population and the dosing sequence of these available options.

关键词： endocrine-resistant     HR+/HER2- advanced breast cancer     randomized clinical trials     meta-analysis     targeted therapy    

HTML PDF 收藏

Low-carbohydrate diets lead to greater weight loss and better glucose homeostasis than exercise: a randomizedclinical trial

《医学前沿（英文）》 2021年 第15卷 第3期   页码 460-471 doi: 10.1007/s11684-021-0861-6

摘要： Lifestyle interventions, including dietary adjustments and exercise, are important for obesity management. This study enrolled adults with overweight or obesity to explore whether either low-carbohydrate diet (LCD) or exercise is more effective in metabolism improvement. Forty-five eligible subjects were randomly divided into an LCD group (n=22) and an exercise group (EX, n=23). The subjects either adopted LCD (carbohydrate intake<50 g/day) or performed moderate-to-vigorous exercise (≥30 min/day) for 3 weeks. After the interventions, LCD led to a larger weight loss than EX (−3.56±0.37 kg vs. −1.24±0.39 kg, P<0.001), as well as a larger reduction in fat mass (−2.10±0.18 kg vs. −1.25±0.24 kg, P=0.007) and waist circumference (−5.25±0.52 cm vs. −3.45±0.38 cm, P=0.008). Both interventions reduced visceral and subcutaneous fat and improved liver steatosis and insulin resistance. Triglycerides decreased in both two groups, whereas low-density lipoprotein cholesterol increased in the LCD group but decreased in the EX group. Various glycemic parameters, including serum glycated albumin, mean sensor glucose, coefficient of variability (CV), and largest amplitude of glycemic excursions, substantially declined in the LCD group. Only CV slightly decreased after exercise. This pilot study suggested that the effects of LCD and exercise are similar in alleviating liver steatosis and insulin resistance. Compared with exercise, LCD might be more efficient for weight loss and glucose homeostasis in people with obesity.

关键词： low-carbohydrate diet     obesity     nonalcoholic fatty liver disease     continuous glucose monitoring     mean sensor glucose    

HTML PDF 收藏

新型立体式网状宫内节育器初步临床观察

邱毅,王磊光,于玲

《中国工程科学》 2014年 第16卷 第5期   页码 39-46

摘要：

为了观察新型立体式网状宫内节育器（3-DR-IUD）的避孕效果及副反应，将152 例志愿受试者随机分为两组，即接受3-DR-IUD组和放置元宫药铜宫内节育器(2-D-IUD)组，每组各76 例，常规放置3-DR-IUD和2-D-IUD。分别于术后1 个月、3 个月、6 个月和12 个月进行随访，了解放置宫内节育器（IUD）后副反应（如腹痛、腰痛、阴道出血持续时间及出血量、白带等）的发生率、带器妊娠率、IUD脱落率、因症取出率、续用率及避孕效果，并利用B超、X光腹部平片检查3-DR-IUD位置等。两组各76 例均成功放置了IUD，术中均无明显疼痛。3-DR-IUD组术后出现白带增多、月经期延长、不规则出血、月经量增多及腰腹部疼痛等副反应6例(7.9%)，而2-D-IUD组出现31例（40.8%），两组比较差异有统计学意义(P<0.000 1)。3-DR-IUD 组无脱落，无带器妊娠者，3 个月时因对硅橡胶过敏取出1 例，12 个月时终止率为1.3 %，续用率为98.7 %（75/76）；2-DIUD组终止率为13.2 %，续用率为86.8 %（66/76），两组比较差异有统计学意义(P=0.009)。实验结果表明，3-DR-IUD具有很好的避孕效果，术后副反应轻微，可为育龄妇女提供新的、安全、高效的IUD。

关键词： 3-DR-IUD     临床实验     副反应     避孕效果    

HTML PDF 收藏

Rare tumors: a blue ocean of investigation

《医学前沿（英文）》 2023年 第17卷 第2期   页码 220-230 doi: 10.1007/s11684-023-0984-z

摘要： Advances in novel drugs, therapies, and genetic techniques have revolutionized the diagnosis and treatment of cancers, substantially improving cancer patients’ prognosis. Although rare tumors account for a non-negligible number, the practice of precision medicine and development of novel therapies are largely hampered by many obstacles. Their low incidence and drastic regional disparities result in the difficulty of informative evidence-based diagnosis and subtyping. Sample exhaustion due to difficulty in diagnosis also leads to a lack of recommended therapeutic strategies in clinical guidelines, insufficient biomarkers for prognosis/efficacy, and inability to identify potential novel therapies in clinical trials. Herein, by reviewing the epidemiological data of Chinese solid tumors and publications defining rare tumors in other areas, we proposed a definition of rare tumor in China, including 515 tumor types with incidences of less than 2.5/100 000 per year. We also summarized the current diagnosis process, treatment recommendations, and global developmental progress of targeted drugs and immunotherapy agents on the status quo. Lastly, we pinpointed the current recommendation chance for patients with rare tumors to be involved in a clinical trial by NCCN. With this informative report, we aimed to raise awareness on the importance of rare tumor investigations and guarantee a bright future for rare tumor patients.

关键词： rare tumors     diagnosis flowchart     treatment strategy     clinical trials recommendation    

HTML PDF 收藏

versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomizedclinical trial

《医学前沿（英文）》 2022年 第16卷 第2期   页码 276-284 doi: 10.1007/s11684-021-0855-4

摘要： We aimed to evaluate the effectiveness and safety of single-course initial regimens in patients with low-risk gestational trophoblastic neoplasia (GTN). In this trial (NCT01823315), 276 patients were analyzed. Patients were allocated to three initiated regimens: single-course methotrexate (MTX), single-course MTX+ dactinomycin (ACTD), and multi-course MTX (control arm). The primary endpoint was the complete remission (CR) rate by initial drug(s). The primary CR rate was 64.4% with multi-course MTX in the control arm. For the single-course MTX arm, the CR rate was 35.8% by one course; it increased to 59.3% after subsequent multi-course MTX, with non-inferiority to the control (difference –5.1%, 95% confidence interval (CI) –19.4% to 9.2%, P=0.014). After further treatment with multi-course ACTD, the CR rate (93.3%) was similar to that of the control (95.2%, P=0.577). For the single-course MTX+ACTD arm, the CR rate was 46.7% by one course, which increased to 89.1% after subsequent multi-course, with non-inferiority (difference 24.7%, 95% CI 12.8%–36.6%, P<0.001) to the control. It was similar to the CR rate by MTX and further ACTD in the control arm (89.1% vs. 95.2%, P=0.135). Four patients experienced recurrence, with no death, during the 2-year follow-up. We demonstrated that chemotherapy initiation with single-course MTX may be an alternative regimen for patients with low-risk GTN.

关键词： gestational trophoblastic neoplasia (GTN)     methotrexate (MTX)     dactinomycin (ACTD)    

HTML PDF 收藏

Overcoming the challenges of conducting translational research in cell therapy

Sowmya Viswanathan, Armand Keating

《医学前沿（英文）》 2011年 第5卷 第4期   页码 333-335 doi: 10.1007/s11684-011-0166-2

摘要： Cell therapy holds promise in addressing a number of unmet medical needs but despite its considerable impetus, faces numerous challenges including support for translational research in this area. Here, we examine the challenges confronting cell therapy research including the limited funding available for translational research partly due to the uncompetitive nature of required validation studies in cell therapy that of necessity are not hypothesis-driven. Other issues include lack of standardization of definitions of cell products, uncertainty regarding optimum preclinical animal models, duplication of efforts to secure regulatory approval and a lack of uniformity of nomenclature for some cell products. Nonetheless, several initiatives to address all of these issues are underway.

关键词： stem cells     clinical trials     funding     animal models     standardization     common definitions    

HTML PDF 收藏

新冠病毒疫苗的下一步效力评价

江湖大川, 张力, 李靖欣,朱凤才

《工程（英文）》 2021年 第7卷 第7期   页码 903-907 doi: 10.1016/j.eng.2021.04.013

HTML PDF 收藏

older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomized

null

《医学前沿（英文）》 2014年 第8卷 第3期   页码 368-375 doi: 10.1007/s11684-014-0360-0

摘要：

This study aimed to evaluate the efficacy of comprehensive therapy based on traditional Chinese medicine (TCM) patterns on older patients with chronic obstructive pulmonary disease (COPD) through a four-center, open-label, randomized controlled trial. Patients were divided into the trial group treated using conventional western medicine and Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen granules, and Yi-Qi Zi-Shen granules based on TCM patterns respectively; and the control group treated using conventional western medicine. A total of 136 patients≥65 years completed the study, with 63 patients comprising the trial group and 73 comprising the control group. After the six-month treatment and the 12-month follow-up period, significant differences were observed between the trial and control groups in the following aspects: frequency of acute exacerbation (P≤0.040), duration of acute exacerbation (P = 0.034), symptoms (P≤0.034), 6-min walking distance (6MWD) (P≤0.039), dyspnea scale (P≤0.036); physical domain (P≤0.019), psychological domain (P≤0.033), social domain (P≤0.020), and environmental domain (P≤0.044) of the WHOQOL-BREF questionnaire; and daily living ability domain (P≤0.007), social activity domain (P≤0.018), depression symptoms domain (P≤0.025), and anxiety symptoms domain (P≤0.037) of the COPD-QOL. No differences were observed between the trial and control groups with regard to FVC, FEV1, and FEV1%.

关键词： chronic obstructive pulmonary disease     older adult     clinical trial     Bu-Fei Jian-Pi granules     Bu-Fei Yi-Shen granules     Yi-Qi Zi-Shen granules    

HTML PDF 收藏

Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial

Li Ni, Zheng Wen, Xiaowen Hu, Wei Tang, Haisheng Wang, Ling Zhou, Lujin Wu, Hong Wang, Chang Xu, Xizhen Xu, Zhichao Xiao, Zongzhe Li, Chenze Li, Yujian Liu, Jialin Duan, Chen Chen, Dan Li, Runhua Zhang, Jinliang Li, Yongxiang Yi, Wei Huang, Yanyan Chen, Jianping Zhao, Jianping Zuo, Jianping Weng, Hualiang Jiang, Dao Wen Wang

《医学前沿（英文）》 2021年 第15卷 第5期   页码 704-717 doi: 10.1007/s11684-021-0853-6

摘要： We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in addition to standard care. The control group was composed of 59 patients who received standard therapy alone. Treatment with SHL was not associated with a difference from standard care in the time to disease recovery. Patients with 14-day SHL treatment had significantly higher rate in negative conversion of SARS-CoV-2 in nucleic acid swab tests than the patients from the control group (93.4% vs. 73.9%, =0.006). Analysis of chest computed tomography images showed that treatment with high-dose SHL significantly promoted absorption of inflammatory focus of pneumonia, which was evaluated by density reduction of inflammatory focus from baseline, at day 7 (mean difference (95% CI), −46.39 (−86.83 to −5.94) HU; =0.025) and day 14 (mean difference (95% CI), −74.21 (−133.35 to −15.08) HU; =0.014). No serious adverse events occurred in the SHL groups. This study illustrated that SHL in combination with standard care was safe and partially effective for the treatment of COVID-19.

关键词： COVID-19     SARS-CoV-2     Shuanghuanglian oral liquid     clinical trial    

HTML PDF 收藏

Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation

Zhaoxiang Bian, Baoyan Liu, David Moher, Taixiang Wu, Youping Li, Hongcai Shang, Chungwah Cheng

《医学前沿（英文）》 2011年 第5卷 第2期   页码 171-177 doi: 10.1007/s11684-011-0132-z

摘要： The reporting standards for randomized controlled trials were first published in 1996 by a group of scientists under the name “CONSORT,” which means consolidated standards of reporting trials. Revisions followed in 2001 and 2010. A draft of the CONSORT for traditional Chinese medicine (TCM) was published in both Chinese and English in 2007. After publication of the draft, comments were solicited from the medical community. Some papers did raise concerns about which items should be included in the CONSORT for TCM such as the rationale of the trial design, intervention, outcome assessment, and adverse events. We have now reached the next step which is the finalization of the CONSORT for TCM. Three tasks remain. First, the major changes in CONSORT statement 2010 should be integrated into the CONSORT for TCM. Second, Chinese drugs from minerals and animals should be included in the guidelines. Finally, agreement must be reached among the working groups. Once the draft is finalized, wide dissemination and co-publication will be considered.

关键词： CONSORT for TCM     reporting standards     future development    

HTML PDF 收藏

原发性肝癌三维适形和调强放疗的基础和临床研究

蒋国梁

《中国工程科学》 2009年 第11卷 第10期   页码 129-136

摘要：

报告三维适形（3-dimensional conformal radiation therapy, 3DCRT）和调强放疗（intensity-modulated radiation therapy, IMRT）治疗原发性肝癌（HCC）的基础和临床研究,建立了3DCRT和IMRT放疗HCC的技术，进行3个临床试验，获得了令人鼓舞的3年总生存率：28 ％～33 ％。治疗并发症主要是放射性肝病（RILD），此并发症的死亡率为76 ％，预防RILD最有效的方法是把对正常肝脏的放射剂量限制在安全的范围内。我国的HCC病人大都伴有肝硬化，伴发的肝硬化损害了肝脏对放射损伤的修复和肝脏再生的能力，他们的放射耐受剂量是（全肝平均剂量）：Child-Pugh A病人23 Gy，Child-Pugh B病人6 Gy，这个耐受量显著低于目前国际上通用的30 Gy。研究建立了用于预测我国HCC病人放疗中发生RILD发生概率的Lyman数学模式，其参数明显不同于国外的模式，并将一整套适合我国国情的HCC放疗技术成功地进行了临床实践，证实了放疗可以作为不能手术肝癌的一种治疗选择。

关键词： 三维适形放疗     束流调强放疗     肝细胞性肝癌     肝脏放射耐受性    

HTML PDF 收藏

单克隆抗体治疗过敏性疾病的研究现状 Review

陈彦, 王炜, 袁慧慧, 李艳, 吕喆, 崔烨, 刘杰, 孙英

《工程（英文）》 2021年 第7卷 第11期   页码 1552-1556 doi: 10.1016/j.eng.2020.06.029

摘要：

过敏性疾病是常见的慢性疾病之一，由变应原在不同器官上引发变态反应，在临床上以不同器官的疾病为主要表现形式，如哮喘、特应性皮炎、鼻-鼻窦炎等，常累及儿童和成人。由于其在世界范围内的广泛流行和对患者生活质量的影响，采用新型生物疗法治疗过敏性疾病的研究业已成为该领域的热点。已知多种因素可促进或触发Th2 型免疫应答，导致2 型细胞因子和免疫球蛋白E（IgE）的产生并参与过敏性疾病的发生发展，因此，开发针对2 型细胞因子和IgE 的单克隆抗体为治疗过敏性疾病提供了新的策略。此外，一些潜在的靶点，如上皮源性预警素-胸腺基质淋巴细胞生成素（TSLP）和白介素33（IL-33）业已进入临床研究阶段。这些新的和潜在的靶点极大地提高了变应性疾病的治疗机会。本文阐述了目前已开发的针对细胞因子、细胞因子受体和IgE 的单克隆抗体在过敏性疾病治疗中的作用，并对这些抗体的临床效果进行了讨论和分析。

关键词： 过敏性疾病     单克隆抗体     抗免疫球蛋白E     细胞因子     临床试验    

HTML PDF 收藏

CAR-T细胞产品的质量控制和非临床研究——一般原则和关键问题 Review

李永红, 霍艳, 于雷, 王军志

《工程（英文）》 2019年 第5卷 第1期   页码 122-131 doi: 10.1016/j.eng.2018.12.003

摘要：

采用嵌合抗原受体T 细胞（chimeric antigen receptor T cells, CAR-T cells）的过继性细胞治疗是一种很有前途的肿瘤免疫治疗策略，近年来发展迅速。CAR-T 细胞是通过基因修饰能够特异性识别肿瘤细胞表面特定抗原的T 细胞，对肿瘤细胞具有强大的杀灭作用。目前CAR-T 细胞在恶性血液病患者中的临床应用已经取得振奋人心的结果，国内外对于CAR-T 细胞针对多种靶点以及用于治疗实体瘤的研究开发形成了很大的热点，越来越多的产品将会进入临床试验和上市使用。这些产品的质量控制和非临床研究对于保障产品安全、有效具有重要意义，同时也具有较大的挑战和困难。本文在相关细胞治疗和基因治疗产品指导原则的基础上，结合CAR-T 细胞产品的具体特点，探讨其质量控制和非临床前研究的一般原则，以及其中的一些关键问题。

关键词： 嵌合抗原受体T细胞     质量控制     非临床研究     安全性     有效性     临床试验     癌症免疫治疗    

HTML PDF 收藏

标题 作者 时间 类型 操作

Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patientswith pneumoconiosis: a pilot double-blind, randomized, and placebo-controlled study

期刊论文

A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against

PAN Jiangang, ZHOU Xing, CHEN Zhiguang, HAN Ruifa

期刊论文

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR

Wenjie Zhu, Binghe Xu

期刊论文

Low-carbohydrate diets lead to greater weight loss and better glucose homeostasis than exercise: a randomizedclinical trial

期刊论文

新型立体式网状宫内节育器初步临床观察

邱毅,王磊光,于玲

期刊论文

Rare tumors: a blue ocean of investigation

期刊论文

versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomizedclinical trial

期刊论文

Overcoming the challenges of conducting translational research in cell therapy

Sowmya Viswanathan, Armand Keating

期刊论文

新冠病毒疫苗的下一步效力评价

江湖大川, 张力, 李靖欣,朱凤才

期刊论文

older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomized

null

期刊论文

Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial

Li Ni, Zheng Wen, Xiaowen Hu, Wei Tang, Haisheng Wang, Ling Zhou, Lujin Wu, Hong Wang, Chang Xu, Xizhen Xu, Zhichao Xiao, Zongzhe Li, Chenze Li, Yujian Liu, Jialin Duan, Chen Chen, Dan Li, Runhua Zhang, Jinliang Li, Yongxiang Yi, Wei Huang, Yanyan Chen, Jianping Zhao, Jianping Zuo, Jianping Weng, Hualiang Jiang, Dao Wen Wang

期刊论文

Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation

Zhaoxiang Bian, Baoyan Liu, David Moher, Taixiang Wu, Youping Li, Hongcai Shang, Chungwah Cheng

期刊论文

原发性肝癌三维适形和调强放疗的基础和临床研究

蒋国梁

期刊论文

单克隆抗体治疗过敏性疾病的研究现状

陈彦, 王炜, 袁慧慧, 李艳, 吕喆, 崔烨, 刘杰, 孙英

期刊论文

CAR-T细胞产品的质量控制和非临床研究——一般原则和关键问题

李永红, 霍艳, 于雷, 王军志

期刊论文